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Pancreatic polypeptide (PP) and neuropeptide Y (NPY) belong to a family of regulatory peptides which 
hold a distinct tertiary structure, the PP-fold, even in dilute aqueous solution. High-affinity receptors, speci- 
fic for both PP and NPY, are described on the rat phaeochromocytoma cell line, PC-12. The binding of 
[1251-Tyr76]PP to PC-I 2 cells was inhibited by concentrations of unlabeled PP which correspond to physio- 
logical concentrations of the hormone, 10~ir-10-9 mol/l. The affinity of the receptor for the neuropeptide, 
NPY, was 102-times lower than that of the PP receptor. C-terminal fragments of both PP (PP24m36) and NPY 
(NPY i3-36) were between IO*- and IO’-times less potent in displacing the radiolabeled 36-amino-acid peptides 
from their respective receptors. It is concluded that PC-12 cells are suited for structure-function studies of 
the PP-fold peptides and studies on the cellular events following cellular binding of PP-fold peptides. 
Neuropeptide Y; Pancreatic polypeptide; 3-Dimensional peptide structure; (PC-12 cell) 
1. INTRODUCTION 
The pancreatic polypeptide fold (PP-fold) fami- 
ly is a group of regulatory peptides containing 36 
amino acids, with a common distinct tertiary struc- 
ture [ 11. The PP-fold consists of a long N-terminal 
polyproline helix followed by a type II &bend and 
a long amphiphilic a-helix [l-4]. The two helices 
are held together by tightly packed, interdigitating 
hydrophobic side chains [l-4]. The C-terminal 
hexapeptide is relatively free-moving and the C- 
terminal amide group, at least, is of crucial impor- 
tance for the biological function [5,6]. Three 
members of the family are known: pancreatic 
polypeptide (PP), a pancreatic hormone [7]; 
neuropeptide Y (NPY), an important neuropeptide 
in both the central and peripheral nervous systems 
[&lo]; and peptide YY (PYY), a hormone from 
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the lower intestine [ll]. The peptides are only be- 
tween 45 and 70% homologous, when the whole 
primary structure is considered [l]. However, the 
key residues of importance for the stability of the 
PP-fold are either identical in all the peptides or 
very conservatively substituted, e.g. Phe for Tyr 
[ 11. The structure of avian PP was determined by 
X-ray crystallography to a resolution of less than 
1 A [2-41. By analogy to the avian structure, a 
computographic image of the PP-fold structure 
has been composed for the other members of the 
family, including the mammalian PPs [l, 121. The 
PP-fold is stable, even in dilute aqueous solution 
as indicated by circular dichroism studies [ 1,3,13]. 
The detailed knowledge of the PP-fold structure 
and its apparent stability under physiological con- 
ditions makes this peptide family particularly 
suited for structure-function studies. 
Receptors for NPY have been demonstrated in 
synaptosomal preparations from brain tissues 
[14-161 and for PYY on enterocytes [17]. Avian 
PP binds specifically to receptors in bird 
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cerebellum [18]. However, no true receptors for 
mammalian PP have been demonstrated, although 
the peptide and its physiological functions in the 
regulation of exocrine pancreatic secretions and 
biliary motility have been known for more than a 
decade [7]. Only high-capacity, low-affinity recep- 
tors of doubtful physiological relevance have been 
detected [19]. The action of PP is demonstrable in 
vivo only, not in in vitro preparations of pan- 
creatic or biliary tissues [20,21]. Thus, it was sug- 
gested that PP must act through nerves [7]. Based 
on the occurrence of receptors for other peptides 
on neuroendocrine cell lines we looked for NPY 
and PP receptors on different phaechromocytoma 
and neuroblastoma cell lines, and here present 
evidence that PC-12 cells have high-affinity recep- 
tors for both PP and NPY. 
2. MATERIALS AND METHODS 
2.1. Radioactive ligands 
Synthetic porcine NPY’-36 was purchased from 
Peninsula (St. Helens, England). Natural purified 
bovine PPi-36 was a generous gift from Ron 
Chance (Eli Lilly, Indianapolis, IN). Both peptides 
were iodinated with carrier-free Nat? (Amer- 
sham, Little Chalfont, England) using the ox- 
idative reagent, 1,3,4,6-tetrachloro-3a,6cY-diphen- 
ylglycouril (Serva) [22]. The chloroglycouril 
(3.7 mg) was dissolved in 2.0 ml dichloromethane 
(Merck) and an Eppendorf test tube (Sarstedt, 
Numbrecht, FRG) was coated with 20 ~1 of this 
solution by gently turning the tube while the 
solvent evaporated. The peptide (5 nmol) was 
dissolved in 40~1 phosphate buffer, pH 7.38 
(precision buffer solution, Radiometer, Copen- 
hagen) and transferred to the coated tube. Na12? 
(1 mCi) was added and the tube was kept on ice. 
After 5 min, 50~1 of the high-performance liquid 
chromatography (HPLC) solvent was added be- 
fore purification on a Nucleosil 300-5 Cis column 
(0.4 x 25 cm) eluted at 50°C at a flow rate of 
1.0 ml/min. Fractions of 0.5 ml were collected 
into tubes containing 0.1 ml of 3 mol/l acetic acid 
containing BSA (100 mg/l). In the purification of 
the NPY tracer, the column was equilibrated and 
eluted isocratically with 35% acetonitrile (Merck) 
in 0.1% trifluoroacetic acid (TFA)/HzO. The two 
peaks of labeled peptide eluting early after the free 
210 
iodine peak were used in the binding experiments. 
These were [“‘I-Tyr’]NPY with a specific activity 
of 500 Ci/mmol and [1251-Tyr36]NPY of 
1900 Ci/mmol as determined in self-displacement 
experiments (details of characterization of ligands 
to be published elsewhere). In the purification of 
the PP tracer, the radiolabeled peptides were 
eluted with a gradient of acetonitrile from 28 to 
50% over 60 min. The major, late peak of radio- 
activity (fig. 1) which, by HPLC characterization 
of tryptic fragments, was shown to be [“‘I- 
Tyr36]PP (not shown) had a specific activity of 
1900 Ci/mmol and was used for binding. 
2.2. Cell culture 
PC-12 cells derived from a rat 
phaeochromocytoma cell line were of subclone 
11-250, kindly provided by Hans Thoenen (Max- 
Planck-Institut fur Psychiatric, Martinsried). 
These cells were originally subcloned from tumors 
induced by PC-12 cells in Diaconess rats. Cells 
were grown in 10% CO2 in Dulbecco’s essential 
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Fig. 1. Purification of “‘I-labeled pancreatic polypeptide 
for receptor binding. HPLC of PP iodinated using 
chloroglycouril as described in detail in the text was 
performed on a Nucleosil Ci8 column eluted with 
TFA/water and a gradient of acetonitrile (- - -). The 
radiolabeled peptide (II) was used for binding 
experiments; this peptide was shown by HPLC 
characterization of tryptic fragments to be mainly 
monoiodinated PP labeled in position 36. The elution 
positions of unlabeled PP and oxidized unlabeled PP are 
indicated by arrows. 
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medium (041-1885, Gibco, Uxbridge, England) 
supplemented with 10% horse serum, 5% fetal calf 
serum (both from Gibco), 1% glutamine, and 
0.1% gentamycin. 
2.3. Binding experiments 
Cells (1.2 x 106) were transferred to petri wells, 
6-well culture plates (Costar, Cambridge, MA), 
which had been pretreated for 1 min with 1 ml per 
well of poly-Lys-Ala (P-1276, 0.2 g/l; Sigma, St. 
Louis, MO) and extensively washed in phosphate- 
buffered saline. After 2 days media were removed, 
and the cells were washed in binding buffer (pH 
7.4) of the following composition (in mmol/l): 
NaCl, 150; KCl, 5; CaCl, 2.5; KHzPO~, 1.2; 
MgzS04, 1.2; NaHCO3, 25; Hepes, 10, sup- 
plemented with 1% BSA. The cells were incubated 
with 0.9 ml binding buffer to which peptide was 
added in 0.05 ml binding buffer followed by 
50000 cpm radiolabeled peptide, dissolved in 
0.05 ml binding buffer. After incubation for 
30 min in a CO2 incubator at 37”C, the incubation 
buffer was removed and cells were washed twice in 
1 ml ice-cold binding buffer before 1 + 0.5 ml of 
lysis buffer was added, 3 mol/l acetic acid with 
urea (8 mol/l) and Nonidet P40 (2070, v/v). The 
lysis mixture was transferred to test tubes before 
counting for 10 min. In all experiments, triplicate 
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Fig.2. Inhibition of “‘I-PP binding to PC-12 cells by Fig.3. Inhibition of “‘1-NPY binding to PC-12 cells by 
members of the PP-fold family. Binding of members of the PP-fold family. Binding of ‘*‘I-NPY 
radioiodinated bovine PP1-36, iZ51-b-PP (l-36), was 
inhibited by purified natural bovine PP’-36 (M , 
was inhibited by synthetic porcine NPY’-36 (M, 
N = 12), synthetic porcine PYY1-3” (0--O, N = 4), 
N = 9), synthetic rat PP’-36 (ti , N = 5) and and naturally purified bovine PP1-36 (A--A , N = 4). 
synthetic porcine NPY1-36 (M, N = 5). Means f Means + SE of the 070 of maximal binding of 
SE of the % of maximal binding of radiolabeled PP are radiolabeled NPY are indicated for each concentration 
indicated for each concentration of peptide. of peptide. 
incubations were performed for each concentra- 
tion of peptide. 
2.4. Peptides used for displacement 
Porcine NPY1-36 and bovine PP1-36 were from 
the same source as those used for radiolabeling. 
Porcine PYY1-36 and rat PP*-36 were both pur- 
chased from Peninsula. PP24-36 was a 
Staphylococcus protease fragment of natural 
bovine PP’-36 generously provided by Melvin 
Johnson and Ron Chance (Eli Lilly). Synthetic 
~~~‘3-36 was generously provided by Rolf 
Hgkanson (University of Lund). 
3. RESULTS 
Specific steady-state binding to PC-12 cells was 
obtained with radiolabeled NPY within 10 min 
and with radiolabeled PP within 30 min at 37°C. 
The PC-12 cells bound 2.48 f 0.61% (mean f SE) 
of the PP label of which 0.44 + 0.07% was 
unspecific binding, i.e. binding in the presence of 
1 x 10e6 mol/l of unlabeled peptide. NPY binding 
was 4.78 + 0.66% of which 1.37 + 0.19% was 
100 
126 
I-NPY 
% OF MAX. 
BOUND 
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unspecific binding. 1251-Tyr36 and 1251-Tyr1 bound 
equally well, however, the latter was generally 
used. 
The specificity of binding was tested in competi- 
tion experiments with different members of the 
PP-fold family (figs 2,3). The binding of 1251-PP 
was inhibited by unlabeled PP at very low concen- 
trations (10-12-10-9 mol/l); 50% inhibition was 
obtained with 6 x lo-” mol/l (fig.2). The number 
of binding sites for PP on PC-12 cells was 
calculated to be 750 per cell, and the dissociation 
constant Kd = 4.5 x 10-l’ mol/l. The potency of 
NPY1-36 in inhibiting PP binding was less than 
10-5-times that of PP. Surprisingly, synthetic rat 
PP1-36 inhibited the binding of the bovine 1251- 
PP1-36 to rat PC-12 cells with a potency of only 
1 J 
-12 -11 -10 -9 -8 -7 -6 
Fig.4. Inhibition of “‘1-NPY and “‘I-PP binding to 
PC-12 cells by C-terminal fragments. (Upper panel) 
Inhibition of 1251-NPY binding by synthetic porcine 
NPY1-36 (o---o, N = 12) and synthetic NPY’3-36 
(o----o, N = 6) is shown. (Lower panel) Inhibition of 
“‘1-PP binding by purified, natural bovine PP1-36 
(ti , N = 9) and an enzymatic fragment of bovine 
PP, PP24-36 (+--+ , N = 3) is shown. Means * SE of 
the % of maximal binding of radiolabeled tracer are 
indicated for each concentration of peptide. The normal counterpart o PC-12 cells (original- 
The PC-12 cell line is a classical cell line for 
studies in neurobiology [23]. In the present paper 
we present evidence for the presence of two distinct 
types of receptors for members of the PP-fold 
family on PC-12 cells. This observation should 
permit further studies on, e.g. secondary 
messenger systems, and other cellular events 
following stimulation with NPY and PP. Also, the 
structure-function relationship of this family of 
peptides can now be studied in more detail, based 
on the knowledge of the distinct three-dimensional 
structure of the PP-fold. Finally, the presence of 
the receptors on a cell line offers unique 
possibilities for isolation and characterization of 
the receptor by, e.g. expression cloning based on 
mRNA from PC-12 cells. 
around 10% of that of unlabeled bovine PP1-36 
(fig.2). 
The binding of radiolabeled NPY was inhibited 
by unlabeled NPY1-36 in a dose-dependent manner 
in the concentration range 10-10-10-7 mol/l; 50% 
inhibition was obtained with 6.0 nmol/l of 
unlabeled NPY1-36 (fig.3). Mathematical transfor- 
mation of the binding data for NPY indicated 
either the presence of more than one type of recep- 
tor or different affinity states of a single receptor 
(not shown). The high-affinity receptor is 
characterized by a maximal binding capacity of 
55 000 binding sites per cell, and a dissociation con- 
stant Kd = 3 nmol/l. PYY1-36 competed with 1251- 
NPY binding to PC-12 cells almost as well as 
NPY’-36, whereas the potency of PP’-36 was less 
than 0.1% of that of NPYie3’j (fig.3). 
A partial structure-binding characterization was 
performed with long C-terminal fragments of the 
peptides (fig.4). NPY’3-36 needed to be added at 
200-times higher concentrations than NPY 1-36 to 
obtain a similar inhibition of ‘251-NPY binding. 
PP 24-36 was also less potent than the intact 
molecule, by a factor of 5 x 103, in inhibiting the 
binding of 1251-PP to PC-12 cells (fig.4). Never- 
theless, PP24-36 was able to prevent totally ‘251-PP 
binding at a concentration of 3 x 10e6 mol/l. This 
finding is in agreement with the observation of a 
full agonistic effect but low potency of PP31W3’j on 
physiological functions [5]. 
4. DISCUSSION 
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ly derived from a phaeochromocytoma) is the 
chromaffin cell of the adrenal medulla. NPY, a 
neurotransmitter predominantly located in the 
sympathetic nervous system [8,24,25], is also 
found in a subset of chromaffin cells [26,27]. In 
fact, PC-12 cells synthesize and release NPY [28]. 
NPY receptors on NPY-producing cells could be 
expected to be ‘presynaptic’. However, with 
respect to specificity, the PC-12 cell receptor 
resembles the postsynaptic, Yi, receptor. The 
biological function of NPY has been characterized 
as a combination of a postsynaptic action, 
mediated through a hypothetical Y 1 receptor and a 
presynaptic action, mediated through a YZ receptor 
[6]. The postsynaptic effects are only observed 
with the intact NPY or PYY molecule, whereas, 
e.g. PYY13-36 can stimulate the hypothetical 
presynaptic receptor equally well to the whole 
molecule [6]. Since the NPY receptor on PC-12 
cells did not bind NPY13-36 as well as NPY’-36, it 
is presumably of a postsynaptic type. The affinity 
of the NPY receptors on PC-12 cells is around 
lo-times less than that reported for brain synap- 
tosomal NPY receptors [15,16]. We find that the 
NPY receptor on PC-12 cells does not discriminate 
well between NPY and PYY, which supports 
observations in biological assays for postsynaptic 
function where PYY is as potent as NPY [6]. 
High-affinity receptors for mammalian PPs 
have not been described previously. It has been 
postulated that PP may act through nerve cells [7], 
and since the effect of PP on its target organs, the 
exocrine pancreas and the biliary system, could be 
considered ‘anticholinergic’, it was expected that 
inhibitory PP receptors would be found on 
cholinergic ganglionic cells. In fact, we initially 
looked for PP receptors on cholinergic cell lines, 
e.g. the NS-20-Y cells, without success. PP per se 
has not previously been suspected as having effects 
on adrenal function and the present observation 
will thus lead to physiological studies in PC-12 
cells and their normal counterpart, chromaffin 
cells. It should be noted that the normal range of 
plasma PP concentrations during e.g. food intake 
and hypoglycemia [29], covers the upper part of 
the dose-inhibition curve for bovine PP’-36 (fig.2). 
The notion that PC-12 cells do have two distinct 
receptors, one for NPY and another for PP, is il- 
lustrated by the lack of potency of PP in displacing 
‘251-NPY and the lack of potency of NPY in 
displacing 1251-PP from binding to the cells (figs 
2,3). Unexpectedly, it was found that synthetic rat 
PP1-36 was rather poor in competing with the 
binding of natural bovine PP1-36 to these rat cells 
(fig.4). The amino acid sequence of rat PP is ex- 
traordinarily poorly conserved in comparison to 
other mammalian species [30,3 11. The difference 
in binding observed here could be due to some er- 
ror in synthesis of the peptide or even in the se- 
quence determination of rat PP. More likely, 
however, it could be a true physiological observa- 
tion. A similar observation has been made in 
guinea pigs which have poorly conserved insulin. 
In this species, other mammalian insulins, e.g. por- 
cine, react better with the insulin receptor than the 
endogenous guinea pig insulin itself [32,33]. 
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